Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

DECOY-7 Slidedeck


Published on

Increase the cell densities of your CHO processes and improve your product yield using our novel DECOY-7 miRNA technology.
We used advanced profiling technologies to identify microRNA 7 (miR-7) as a key contributor to improved CHO bioreactor performance following a temperature shift from 37°C to 31°C. Subsequent functional studies using mimics and inhibitors confirmed the potential of miR-7 as a genetic engineering target within CHO cells, whereby depletion has a beneficial effect on some of the traits desirable in production CHO cells, particularly increasing cell density during the early growth phase and viability during later culture and doubling product yield of a model secreted glycoprotein.
These features together have the potential to increase per-run profitability, decrease time required to deliver requisite titres and decrease downstream purification time. Cells grow to a higher density and last longer in culture, resulting in increased per-run titres, increased per-run profitability and decreased time required to deliver product titres. Cell viability is improved, resulting in less contaminating protein from dead cells, facilitating downstream purification.

Published in: Science
  • Be the first to comment

  • Be the first to like this

DECOY-7 Slidedeck

  1. 1. N a t i o n a l I n s t i t u t e F o r C e l l u l a r B i o t e c h n o l o g y Increasing Biopharma production efficiency using DECOY-7 N a t i o n a l I n s t i t u t e f o r C e l l u l a r B i o t e c h n o l o g y , D u b l i n C i t y U n i v e r s i t y , D u b l i n , I r e l a n d e m m a . o n e i l l @ i n v e n t . d c u . i e
  2. 2. Biopharma Challenges • High Cost of Biologics Production • Greater Demands on Cell Line Development • Higher Titres • Higher Cell Densities • Greater pressure on pipelines (turnaround, etc.) Greater Efficiency
  3. 3. Improving processes using miRNAs microRNAs: • Post-transcriptional regulators • Many targets • Known to influence many processes in cell • Not translated
  4. 4. miRNA-7 as a Process Target • microRNA-7 (miR-7) • Active following temperature shift (37°C-31°C) • miR-7-depletion tool: DECOY-7 • Functional studies demonstrate miR-7 depletion has a beneficial effect on CHO bioreactor performance: • increased cell density • increased viability • US8,476,244) EP 2046970 B1 Gammell et al. 2007. Initial identification of low temperature and culture stage induction of miRNA expression in suspension CHO-K1 cells. Journal of Biotechnology, 130, 3, pp213-218 Barron et al. 2011. Engineering CHO cell growth and recombinant protein productivity by overexpression of miR-7. J.Biotechnology 151(2):204-11 Sanchez et al. 2013. MiR-7 triggers cell cycle arrest at the G1/S transition by targeting multiple genes including Skp2 and Psme3. PLOS One. 8(6):e65671 increased product yield
  5. 5. DECOY-7: Cell Density Ctrl K1 DECOY-7 K1
  6. 6. DECOY-7: Viability Ctrl K1 DECOY-7 K1
  7. 7. DECOY-7: Cell Productivity Ctrl K1 DECOY-7 K1
  8. 8. What DECOY-7 means for you • These features together have the potential to: • increase per-run profitability, • decrease time required to deliver requisite titres, • facilitate downstream purification
  9. 9. How we can work with you Collaborate to find a comprehensive solution to your upstream cell line development challenges; - Transient transfection of your existing processes (as a media additive) - Licence/technology transfer to implement DECOY-7 under your in-house control - Collaborative research on your specific cell lines at the NICB
  10. 10. Scientific Team Biopharma & CHO Cell Engineering Group Multidisciplinary research centre, with over 25 years experience in integrated research in fundamental and applied cellular biotechnology, molecular cell biology and biological chemistry The mission of the NICB is to provide targeted and applied solutions to challenges facing the Biopharma industry, utilising our unique multi-disciplinary team, our extensive clinical & industry network and our collaborative problem- solving expertise to deliver value for stakeholders, collaborators and patients.
  11. 11. N a t i o n a l I n s t i t u t e F o r C e l l u l a r B i o t e c h n o l o g y Contact details N i a l l B a r r o n , D i r e c t o r, N I C B e : n i a l l . b a r r o n @ d c u . i e / t : + 3 5 3 1 7 0 0 5 8 0 4 P a d r a i g D o o l a n , S e n i o r R e s e a r c h F e l l o w, N I C B e : p a d r a i g . d o o l a n @ d c u . i e / t : + 3 5 3 1 7 0 0 5 7 9 6 E m m a O ’ N e i l l , D i r e c t o r o f B u s i n e s s D e v e l o p m e n t , L i f e S c i e n c e s D C U e : e m m a . o n e i l l @ i n v e n t . d c u . i e / t : + 3 5 3 1 7 0 0 7 7 4 1